Capital Guardian Trust Co. Decreases Stake in Eli Lilly and Company (NYSE:LLY)

Capital Guardian Trust Co. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 57.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 385,458 shares of the company’s stock after selling 526,658 shares during the period. Capital Guardian Trust Co.’s holdings in Eli Lilly and were worth $31,723,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after acquiring an additional 1,610,885 shares in the last quarter. BlackRock Inc. boosted its stake in Eli Lilly and by 2.1% during the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after buying an additional 1,323,259 shares during the period. State Street Corp lifted its position in shares of Eli Lilly and by 1.6% during the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after purchasing an additional 651,424 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Eli Lilly and by 8.4% during the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after purchasing an additional 708,597 shares in the last quarter. Finally, Janus Capital Management LLC lifted its position in shares of Eli Lilly and by 2.8% during the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after purchasing an additional 237,619 shares in the last quarter. Hedge funds and other institutional investors own 76.43% of the company’s stock.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total value of $17,796,050.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 628,588 shares of company stock valued at $53,399,536. Insiders own 0.20% of the company’s stock.

LLY has been the topic of several analyst reports. BMO Capital Markets reaffirmed a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies reiterated a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price target (down previously from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $90.25.

Eli Lilly and Company (LLY) traded down $0.74 during trading on Wednesday, hitting $85.32. The company had a trading volume of 3,130,937 shares, compared to its average volume of 3,670,362. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a 1-year low of $66.39 and a 1-year high of $89.09. The company has a market cap of $94,231.72, a P/E ratio of 20.92, a PEG ratio of 1.88 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the previous year, the firm earned $0.88 earnings per share. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. sell-side analysts anticipate that Eli Lilly and Company will post 4.21 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.44%. Eli Lilly and’s payout ratio is 98.58%.

TRADEMARK VIOLATION WARNING: This report was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://stocknewstimes.com/2017/12/06/capital-guardian-trust-co-has-31-72-million-stake-in-eli-lilly-and-company-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply